Location: India (serving global clients) Website: i3cglobal.com

i3CGlobal is a specialist medical device and IVD regulatory consulting firm with hands-on expertise across the full 510(k) submission lifecycle. The team works directly with Indian manufacturers and international device companies seeking FDA clearance, covering predicate research, substantial equivalence argumentation, technical file preparation, performance testing coordination, and FDA query responses.

Beyond 510(k), i3CGlobal supports clients across EU MDR, UK MHRA, and CDSCO — making them a strong choice for companies pursuing multi-market regulatory strategies in parallel.

Key services: 510(k) strategy and submission, predicate device analysis, biocompatibility testing coordination, QMS gap assessment (21 CFR Part 820 / ISO 13485), FDA correspondence support, IVD regulatory consulting

Best for: Indian manufacturers entering the US market; companies needing combined FDA + EU MDR or CDSCO strategy

Location: Hyderabad, India Website: freyrsolutions.com

Freyr is a large regulatory affairs firm with a dedicated medical device practice. They offer 510(k) consulting alongside broader FDA regulatory services and have experience with Class II devices across multiple product categories.

Location: US-headquartered, with India delivery teams Website: rcainc.com

RCA brings US-based regulatory expertise with cost-efficient delivery through India operations. Suitable for companies that want FDA-resident strategic oversight combined with offshore execution.

Location: Global, India presence Website: emergobyul.com

EMERGO is one of the most recognised names in global medical device regulatory consulting. Their India team supports 510(k) submissions as part of a wider multi-jurisdictional offering including CE marking and CDSCO.

Location: India operations Website: qualtekinternational.com

Qualtek offers 510(k) consulting with particular strength in quality management system preparation and ISO 13485 implementation alongside submission support.

Location: India Website: medrina.in

Medrina focuses specifically on medical device regulatory affairs in India and the US. They support 510(k) preparation for SME manufacturers looking for focused, cost-effective consulting.

1. Device Classification & Pathway Determination Confirm your device is Class II and eligible for 510(k). Some devices may qualify for De Novo or require PMA.

2. Predicate Device Selection Identify one or more legally marketed predicate devices with the same intended use and technological characteristics. This is the cornerstone of substantial equivalence.

3. Substantial Equivalence Argumentation Build a structured comparison of your device against the predicate covering intended use, technological characteristics, performance data, and any differences that require supporting data.

4. Performance Testing Coordinate required testing — bench performance, biocompatibility per ISO 10993, sterilisation validation, electrical safety (IEC 60601-1), software documentation (IEC 62304 if applicable), and any device-specific guidance.

5. Technical Documentation Compilation Prepare the 510(k) summary or statement, device description, substantial equivalence discussion, proposed labelling, and all supporting test reports.

6. eCopy Submission via FDA ESG Submit through the FDA Electronic Submissions Gateway with correct formatting per the Refuse to Accept checklist.

7. FDA Review & AI Response Manage the interactive review phase, responding promptly and accurately to any Additional Information requests from the FDA reviewer.

H2: Frequently Asked Questions

What is a 510(k) submission? A 510(k) is a premarket notification submitted to the FDA demonstrating that a medical device is substantially equivalent to a legally marketed predicate device. Clearance is required before a Class II device can be marketed in the United States.

How long does the FDA 510(k) review take? The FDA’s standard review goal is 90 days for Traditional 510(k)s. However, total time to clearance including preparation and any AI response cycles typically ranges from 9 to 15 months.

Can Indian companies submit a 510(k) directly to the FDA? Yes. Foreign manufacturers can submit 510(k)s directly. The device must be manufactured in compliance with FDA QSR (21 CFR Part 820) and the company may benefit from appointing a US Agent.

What is the FDA 510(k) clearance fee in 2026? FDA user fees are updated annually. For FY2026, the standard 510(k) fee is approximately USD 21,000 (small businesses may qualify for a reduced fee — check the FDA website for the current schedule).

Do I need ISO 13485 certification to get 510(k) clearance? ISO 13485 is not a formal FDA requirement, but having a compliant QMS that aligns with 21 CFR Part 820 is essential. Many consultants recommend pursuing ISO 13485 in parallel, particularly for companies also targeting EU MDR or MDSAP markets.

What makes i3CGlobal different from other 510(k) consultants in India? i3CGlobal combines deep technical expertise in medical device and IVD regulatory affairs with a multi-jurisdictional capability — meaning they can support your FDA 510(k) alongside EU MDR, UK MHRA, and CDSCO registrations under a unified regulatory strategy.

---

Closing CTA section (H2): Ready to Start Your FDA 510(k) Submission?

i3CGlobal’s regulatory team has the expertise to take your device from classification through clearance. Whether you’re preparing your first 510(k) or responding to an FDA AI request, we provide the technical rigour and strategic guidance your submission needs.

[Contact i3CGlobal for a Free 510(k) Consultation]

---

Suggested internal links to add:

• Your FDA 510(k) consulting service page
• CDSCO registration page
• EU MDR / CER writing service page
• ISO 13485 service page (if you have one)

Suggested schema to add:

• FAQPage JSON-LD for the FAQ section
• Article JSON-LD with author, datePublished, dateModified

The following information needs to be given importance in the clinical evaluation of reusable Surgical Class I devices:

~ Durability and Material Integrity: The clinical evaluation concerning reusable Class I devices covers material integrity and durability, so the device can withstand multiple cycles of sterilization, cleaning, and disinfection without compromising performance or structural integrity.

~ Sterilization Validation: A rigorous process for sterilization should maintain the sterility of the device during its use; hence, the clinical evaluation will also involve data on the process of sterilization validation, and the ability of the device to remain sterile after multipurpose.

During the clinical evaluation, these are coming under the preclinical data that was retrieved from the manufacturer.

~ Risk management: The clinical evaluation should incorporate risk management strategies to prevent device reuse, such as preventing infection vectors from improper cleaning or sterilization and ensuring wear and tear do not compromise the device’s function or safety

The following information needs to be given importance in the clinical evaluation of Class I measuring devices:

~ Accuracy Testing: The device must undergo clinical testing to ensure accurate measurements compared to established standards, demonstrating its ability to deliver precise and reliable measurements across various conditions, demonstrating its reliability.

During the clinical evaluation, this is captured from the preclinical performance test evaluation that was retrieved from the manufacturer.

~ Performance Consistency: It is essential that the device performs consistently over time. The device’s long-term stability and performance across various user groups and environments must be consistently assessed in clinical evaluations.

~ User Training and Usability: The clinical evaluation should evaluate the user interface and the effectiveness of user training for accurate use of measuring devices, ensuring ease of use for healthcare professionals and patients.

The following information needs to be given importance in the clinical evaluation of Class I sterile devices:

~ Sterilization Validation: The clinical evaluation comprises documentation on the sterilization method utilized, such as autoclaving, radiation, or gas sterilization that complies with international sterilization standards, which is effective in eliminating microorganisms.

~ Packaging Integrity: Packaging of sterile devices becomes an important factor in maintaining sterility, and clinical evaluations should also encompass tests concerning materials and design that provide maximum protection of the device against contamination.

~ Infection Control: Clinical data should show the device’s safety record, including infection rates, adverse events, and complications, indicating its intended use does not cause infections or complications.

Shelf Life: Testing long-term stability where the device’s performance and functionality are checked after regular intervals up to its shelf life. These are generally done by storing the device under conditions specified like ambient temperature and humidity for extended periods.

POST-MARKET SURVEILLANCE

Manufacturers of Class I devices need to EU MDR article 83 to perform PMS activity. This involves creating a detailed plan and reporting the results. The report should be updated whenever necessary and must be readily available to provide to the competent authorities upon request.

CONCLUSION

The Class I medical devices according to the EU MDR have a low level of risk devices, but they still require an evaluation by a Notified Body. Class I devices have three subclasses: Class I Reusable Surgical Devices, Class I measuring Devices, and Class I sterile Devices.

Continuous revision of a Clinical Evaluation Report (CER) is very important because it pursues constant demonstrating of safety and performance through clinical evidence during the whole life of a device.

Manufacturers must also plan, establish, document, implement, maintain, and update a post-market surveillance system proportionate to the risk class and appropriate for the device type

STAGE 0 DEFINITION OF SCOPE OF CLINICAL EVALUATION

Before clinical evaluation, the manufacturer should define its scope based on the essential requirements and nature and history of the device. This is called scoping. Scope involves identification of pertinent data, description of the device under evaluation, and clinical evaluation plan.

STAGE 1 IDENTIFICATION OF PERTINENT DATA

Data generated and held by the manufacturer

All premarket clinical investigations and relevant preclinical studies

All clinical data generated from risk management activities and PMS programs including PMCF studies, PMS reports, literature search and evaluation reports, incident reports, complaints regarding safety and performance, analysis of the explanted device, use of the custom-made device, and other user report.

Data retrieved from the literature

A literature search is used to identify data for establishing Clinical data relevant to the device under evaluation, Current knowledge /state of art including standards and guidance documents, data related to benchmark devices, critical components, and medical alternatives.

The searching strategy should be thorough and objective and contain all favorable and unfavorable data. The literature search should be documented. The main sources of literature are:

• Scientific literature databases e.g., Medline or PubMed, EMBASE/Excerpta Medica, COCHRANE CENTRAL trials register, TRIP
• Internet searches e.g.: google scholar, inform it, manufacturer website
• Nonpublished data e.g., label and IFU, implant registries information, data presented in congress,
• Citations e.g., Scopus, web of science

Objective, non-biased, systemic search and review methods should be used. Examples are.

• PICO (patient characteristics, type of intervention, control, and outcome queries)
• PRISMA (the preferred reporting items for systematic reviews and meta-analyses)
• MOOSE proposal (meta-analysis of observational studies in epidemiology)

STAGE 2 APPRAISAL OF PERTINENT DATA

Explains the criteria used by the evaluators for appraising data sets, Summarizes the pertinent data sets (methods, results, conclusion of the authors), Evaluates their methodological quality, scientific validity, the relevance for the evaluation, the weighting attributed to the evidence, and any limitations, present justifications for rejecting certain data and documents. The following criteria should be considered.

• OCEBM (Oxford Centre for Evidence-Based Medicine) level of evidence has been established for the clinical data appraisal
• Data are checked for methodological quality and scientific validity
• MQVS is established through questionnaires and the identification of relevant data
• Relevance of data to clinical evaluation is checked by determining pivotal and other data
• Type of appraisal may be qualitative and quantitative

STAGE 3 ANALYSIS OF THE CLINICAL DATA

The goal of the analysis stage is to determine if the appraised data sets for a medical device demonstrate compliance with essential requirements about the clinical performance and safety of the device, according to its intended purpose.

To demonstrate compliance, the evaluators should: Use sound methods, make a comprehensive analysis, determine if additional clinical investigations or other measures are necessary, and Determine PMCF needs. The procedure includes.

• Conformity assessment with the requirement of safety
• Conformity assessment with the requirement of acceptable risk-benefit profile
• Evaluation of the description of the intended purpose of the device
• Evaluation of the device’s benefits to the patient
• Quantification of benefit to the patient
• Evaluation of clinical risks of devices
• Evaluation of acceptability of risk-benefit profile
• Conformity assessment with the requirement on performance
• Conformity assessment with the requirement on the acceptability of undesirable side effects

Analysis and conclusions of evaluators should fulfill all essential requirements about the clinical properties of the device (MDD ER1, ER3, ER6; AIMDD ER1, ER2, ER5)

STAGE 4 THE CLINICAL EVALUATION REPORT (CER)

A clinical evaluation report shall be compiled to document the clinical evaluation and its output. it should provide enough detail for understanding search criteria, available data, all assumptions made, and all conclusions reached. It involves identification, collection, appraisal, and analysis of the premarket and post-market clinical data of the medical device for the demonstration of compliance to MDR GSPR. procedure involves.

• Organization of clinical evaluation report
• Method of explaining each section
• Content of each section
• Scope of the clinical evaluation
• Clinical background, current knowledge, and state of art
• Device under evaluation
• Summary and appraisal of clinical data
• Analysis of clinical data
• Clinical evaluation report conclusion
• Qualification of the responsible evaluators
• Date of the next evaluation
• Dates and signature
• Declaration of interest and cv of the clinical evaluator

DEMONSTRATION OF EQUIVALENCE

Clinical, technical, and biological characteristics shall be taken into consideration for the demonstration of equivalence, and general information for assuming equivalence as mentioned in appendices A1 of MEDDEV 2.7/1 rev 4 guidelines.

• Equivalence shall only be based on a single device
• All three characteristics (clinical, biological, and technical) should be fulfilled
• The differences between the device under evaluation and the device presumed to be equivalent should be identified, fully disclosed, and evaluated.
• Comparative drawings and pictures can be included
• If the equivalent device is manufactured via special treatment, it is considered as the demonstration for equivalence

The procedure mainly involves the identification of an equivalent device whether it is a CE marked or non-CE marked device as equivalent and evaluation of identified equivalent device based on its clinical, biology, and technical characteristics.

CONCLUSION

• The main goal of the clinical evaluation is to demonstrate the safety and performance of the medical device in clinical use.
• Clinical evaluation consultants for medical devices must possess cross-platform proficiency and in-depth understanding of MDR article 61 and MEDDEV 2.7/1 Rev 4.
• Traceability of the literature search by specifying search terms, links, and databases searched.
• Inclusion, exclusion, evaluation, definition, and documentation of applied criteria are necessary.
• Evaluation of literature according to quality and publication.
• Comparability of the evaluated product in technical, clinical, and biological aspects.

AUTHOR

Firsana Gasly is a pharmacy graduate of Kerala University of Health Sciences with a Diploma in Clinical Research And Management. Currently works as a consultant and technical writer in the medical device Clinical Evaluation department at I3CGlobal.